Company intelligence
CARB-X
Non-profit global partnership funding the development of products that target the most serious drug-resistant bacteria
About CARB-X
CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) is a global non-profit partnership dedicated to supporting early-stage antibacterial research and development to address the rising threat of drug-resistant bacteria. CARB-X supports innovative therapeutics, preventatives and rapid diagnostics. CARB-X is led by Boston University and funded by a consortium of governments and foundations. CARB-X funds only projects that target the most serious, resistant bacteria identified on global priority lists, syndromes with the greatest global morbidity and mortality, and performance characteristics necessary for patients.
Verified activity
Signals from CARB-X
3 published signals
Capital & Finance
CARB-X product developer VAXDYN secured a Series A financing round of €11 million to support the Phase 1 clinical trial of its lead vaccine candidate K-VAX.
Reported by CARB-X
Capital & Finance
CARB-X announced the second cycle of the 2026 funding round for the 2026 AMR funding round, with applications accepted from 10 November 2026 to 23 November 2026.
Reported by CARB-X
Capital & Finance
CARB-X supports LimmaTech Biologics AG preventatives programs including LTB-SA7 since 2017 and LTB-NG6 since 2024, providing over $47.3 million in funding and customized technical support to advance them from hit-to-lead to first-in-human clinical trials.
Reported by CARB-X